Поиск

Автор

Ключевое слово

Коллекция

Дополнительно:

Период публикации

Научный руководитель

Оппонент

По вашему запросу найдено документов: 640

Страница 8 из 64

Mzb1 protects against myocardial infarction injury in mice via modulating mitochondrial function and alleviating inflammation

Zhang, Lu, Wang, Yi-ning, Ju, Jia-ming, Shabanova, Azaliia, Li, Yue, Fang, Ruo-nan, Sun, Jia-bin, Guo, Ying-ying, Jin, Tong-zhu, Liu, Yan-yan, Li, Tian-yu, Shan, Hong-li, Liang, Hai-hai, Yang, Bao-feng (2020)

mitochondrial function and reducing inflammatory signaling pathways, implying a promising therapeutic target

Circulating exosome long non-coding RNAs are associated with atrial structural remodeling by increasing systemic inflammation in atrial fibrillation patients

Yuan, Yue, Han, Xuejie, Zhao, Xinbo, Zhang, Haiyu, Vinograd, Asiia, Bi, Xin, Duan, Xiaoxu, Cao, Yukai, Gao, Qiang, Song, Jia, Sheng, Li, Li, Yue (2024)

remodeling, which bring valuable insights into improving prognosis and therapeutic targets for AF. © 2024 Yue

RRM2 Mediates the Anti-Tumor Effect of the Natural Product Pectolinarigenin on Glioblastoma Through Promoting CDK1 Protein Degradation by Increasing Autophagic Flux

Jiang, HP, Zhang, DZ, Aleksandrovich, KD, Ye, JY, Wang, LX, Chen, XF, Gao, M, Wang, XZ, Yan, T, Yang, H, Lu, EZ, Liu, WW, Zhang, C, Wu, JN, Yao, PL, Sun, ZY, Rong, X, Timofeevich, SA, Mahmutovich, SS, Zheng, ZX, Chen, X, Zhao, SG (2022)

, and RRM2 may be a potential therapeutic target and a prognosis and predictive biomarker in GBM patients.

Комбинированная таргетная терапия ингибиторами BRAF и MEK в сочетании с иммунотерапией (атезолизумаб + вемурафениб + кобиметиниб) при метастатической меланоме кожи (клинический случай)

Combination BRAF/MEK Inhibitor Targeted Therapy and Immunotherapy (atezolizumab + vemurafenib + cobimetinib) for Metastatic Cutaneous Melanoma: Clinical Case

В. Е. Аскаров, V. E. Askarov, А. В. Султанбаев, A. V. Sultanbaev, К. В. Меньшиков, K. V. Menshikov, В. С. Чалов, V. S. Chalov, Н. И. Султанбаева, N. I. Sultanbaeva, И. А. Меньшикова, I. A. Menshikova (Креативная хирургия и онкология, №2, 2025)

Combination BRAF/MEK Inhibitor Targeted Therapy and Immunotherapy (atezolizumab + vemurafenib

Editorial: Cardio-Protection and Heart Repair: New Drugs, Targets and Approaches

Zagidullin, N., Cai, B., Zhu, H. (2021)

Editorial: Cardio-Protection and Heart Repair: New Drugs, Targets and Approaches

ЭПИГЕНЕТИЧЕСКАЯ МОДУЛЯЦИЯ В МЕДИЦИНЕ: РЕГУЛЯЦИЯ ГЕННОЙ ЭКСПРЕССИИ В КОНТЕКСТЕ ПАТОГЕНЕЗА И ТЕРАПИИ

EPIGENETIC MODULATION IN MEDICINE: REGULATION OF GENE EXPRESSION IN THE CONTEXT OF PATHOGENESIS AND THERAPY

Повреждение и восстановление ДНК при глиобластоме: новые перспективы терапии

DNA Damage and Repair in Glioblastoma: Emerging Therapeutic Perspectives

И. Ф. Гареев, I. F. Gareev, О. А. Бейлерли, O. A. Beylerli, С. А. Румянцев, S. A. Roumiantsev (Креативная хирургия и онкология, №2, 2025)

DNA Damage and Repair in Glioblastoma: Emerging Therapeutic Perspectives

Enhancers of mesenchymal stem cell stemness and therapeutic potency

Al-Azab, Mahmoud, Idiiatullina, Elina, Safi, Mohammed, Hezam, Kamal (2023)

and degenerative diseases. They have demonstrated considerable and prospective therapeutic potentials even though

Therapeutic drug monitoring (TDM) as intervention: A cross-sectional analysis of characteristics of 173 registered clinical trials

Zhao, Shanshan, Zaytseva, Olga, Zaytseva, Olga, Zhang, Boquan (2022)

Background: To examine fundamental characteristics of clinical trials with therapeutic drug

ДОСТИЖЕНИЯ В ОБЛАСТИ ИММУНОТЕРАПИИ: РЕВОЛЮЦИЯ В ЛЕЧЕНИИ РАКА И ЗА ЕГО ПРЕДЕЛАМИ С ПОМОЩЬЮ ТАРГЕТНОЙ ТЕРАПИИ

ADVANCEMENTS IN IMMUNOTHERAPY: REVOLUTIONIZING CANCER TREATMENT AND BEYOND WITH TARGETED THERAPIES

Аллаярова, Д.Д., Мишина, А.Н., Allayarova, D.D., Mishina, A.N. (2024)

ADVANCEMENTS IN IMMUNOTHERAPY: REVOLUTIONIZING CANCER TREATMENT AND BEYOND WITH TARGETED THERAPIES

Страница 8 из 64